From The Advisory Board

Use of Aromatase Inhibitors in Advanced Endometrial Cancer

Use of Aromatase Inhibitors in Advanced Endometrial Cancer

This article reviews the current evidence for the role of aromatase inhibitors (AIs) in the treatment of advanced stage or recurrent endometrial cancer.

A Glimpse of ASH

A Glimpse of ASH

By

Dr Isabel Cunningham discusses some of the important studies presented at the 2016 ASH meeting.

Hot Topics From the 2015 Gastrointestinal Cancers Symposium

Hot Topics From the 2015 Gastrointestinal Cancers Symposium

By

Steven J. Cohen, MD, CTA Advisory Board member highlights key science from the 2015 Gastrointestinal Cancer Symposium.

Review of CHAARTED Trial Results

Review of CHAARTED Trial Results

By

CTA Advisory Board member, Neal Shore, MD, puts CHAARTED trial results into context.

What to Consider When It Comes to Surgery in Elderly Patients With Cancer

What to Consider When It Comes to Surgery in Elderly Patients With Cancer

By

Dr. Jeffrey Farma provides his insight on treating the elderly patient population in the surgical oncology setting.

Improving Survival in Advanced NSCLC: Multiple Lines of Chemotherapy Make a Difference

Improving Survival in Advanced NSCLC: Multiple Lines of Chemotherapy Make a Difference

By

Oncologists who care for non-small cell lung cancer (NSCLC) patients need to develop management strategies.

The Resurgence of Interest in Immune Therapy for Metastatic Renal Carcinoma

The Resurgence of Interest in Immune Therapy for Metastatic Renal Carcinoma

By

Immune therapies hold substantial promise to improve therapeutic options for patients with metastatic renal cancer.

Lost in Translation: Communicating with Newly Diagnosed Cancer Patients

Lost in Translation: Communicating with Newly Diagnosed Cancer Patients

By

Dr. Dizon and patient advocate Katherine O'Brien discuss the difficulty of communicating cancer and give advice on common miscommunications.

Liberia's Only Internist Dies of Ebola: Remembering Dr. Abraham Borbor

Liberia's Only Internist Dies of Ebola: Remembering Dr. Abraham Borbor

By

Dr. Burtness, a member of the Cancer Therapy Advisory Board, reflects on the loss of Dr. Abraham Borbor, the only certified internist in Liberia who recently died of Ebola.

Reflections on Patient Perspectives and Survivorship from the 2013 Breast Cancer Symposium

Reflections on Patient Perspectives and Survivorship from the 2013 Breast Cancer Symposium

By

ChemotherapyAdvisor.com Editorial Board Member Don S. Dizon discusses survivorship issues from the 2013 Breast Cancer Symposium.

Q&A with Mark Socinski, MD, on the POINTBREAK Trial of Maintenance Therapy for NSCLC

Q&A with Mark Socinski, MD, on the POINTBREAK Trial of Maintenance Therapy for NSCLC

By

Editorial Advisory Board member Dr. Socinski discusses the key clinical insights brought to light by the POINTBREAK trial, presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

Dr. Jeffrey Farma Offers Overview of Translational Research at ASCO GI

Dr. Jeffrey Farma Offers Overview of Translational Research at ASCO GI

By

An expert reviews the new maintenance, second- and third-line therapies for colorectal cancer treatment presented at the 2013 Gastrointestinal Cancers Symposium.

Active Surveillance for Low-Risk Prostate Cancer May Improve Quality of Life

Active Surveillance for Low-Risk Prostate Cancer May Improve Quality of Life

By

In this article, Advisory Board member Neal Shore, MD, FACS, discusses barriers to clinicians recommending active surveillance for men with low-risk prostate cancer.

New Treatments for Metastatic Colorectal Cancer

New Treatments for Metastatic Colorectal Cancer

By

Several new therapies for metastatic colorectal cancer have been developed and refined, changing the way the disease can be treated.

Sentinel Lymph Nodes for Melanoma: To Biopsy or Not?

Sentinel Lymph Nodes for Melanoma: To Biopsy or Not?

By

Advisory Board Member Dr. Farma reviews the current recommendations for using sentinel lymph node biopsy in patients with melanoma.

A 57-Year-Old Male with Rising PSA and Prior Negative Transrectal Biopsies

A 57-Year-Old Male with Rising PSA and Prior Negative Transrectal Biopsies

By

This patient, who had an increasing PSA level, was found to have abnormal PCA3 urine test results.

The Changing Landscape of Urology

The Changing Landscape of Urology

Advisory Board member Neal D. Shore, MD, FACS relates how vital it is that urologists recognize the changing demands of the field.

An Exclusive Interview with Steven Cohen, MD

An Exclusive Interview with Steven Cohen, MD

Dr. Steven Cohen comments on the 2012 ASCO Annual Meeting and the standard of care for gastrointestinal malignancies.

An Exclusive Interview with Edith Perez, MD

An Exclusive Interview with Edith Perez, MD

By

Dr. Perez comments on the 2012 ASCO Annual Meeting and the standard of care for breast malignancies.

Dr. Sergio A. Giralt Offers Commentary on Hematologic Oncology Coverage at ASCO 2012

Dr. Sergio A. Giralt Offers Commentary on Hematologic Oncology Coverage at ASCO 2012

By

Initial salvage treatment with allogenic stem cell transplant (ASCT) is feasible and yields superior outcomes to salvage chemotherapy in acute myeloid leukemia (AML) patients.

Dr. E. David Crawford: Renal Cell Carcinoma Case Study

Dr. E. David Crawford: Renal Cell Carcinoma Case Study

Dr. E. David Crawford, Head Urologic Oncology at the University of Colorado, presents his case study on renal cell carcinoma (RCC).

Case Study: Castrate-Resistant Prostate Cancer

Case Study: Castrate-Resistant Prostate Cancer

By

Although there are new therapies for M1CRPC patients and others pending, ideal sequencing regimen is still not certain.

Crizotinib Treatment in ROS1-positive NSCLC Patients: A Case Study

Crizotinib Treatment in ROS1-positive NSCLC Patients: A Case Study

By

Although prevalence of cytogenetic abnormality in tumor biopsy is low, finding one or more abnormalities can expand the patient's treatment options.

Treatment Options Emerge for Metastatic Castrate Resistant Prostate Cancer

Treatment Options Emerge for Metastatic Castrate Resistant Prostate Cancer

By

Dr. E. David Crawford, an internationally renowned expert in the treatment of metastatic castrate resistant prostate cancer, offers his predictions about emerging treatment options and how they will fit into the current regimens.

Optimal Induction Therapy for Multiple Myeloma

Optimal Induction Therapy for Multiple Myeloma

The optimal treatment of multiple myeloma today requires a multidisciplinary approach. The advent of novel therapeutic agents has opened new avenues of therapy, which although extremely effective, can be associated with significant toxicities. A team approach to treatment of the multiple myeloma patient goes a long way in reducing the potential for serious complications during induction and consolidation therapy.

Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer Refractory to BCG

Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer Refractory to BCG

Approximately 80% of patients with bladder cancer present with non-muscle-invasive disease (NMIBC). Of these, 15 to 25% will eventually develop muscle-invasive bladder cancer, and there are a number of known predictors of progression to invasive disease.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs